Loading the records…
Ed Case (D-HI) sold $1K-$15K of $PG (Procter & Gamble Company) on Dec 1, 2025.
HillSignal flagged 4 timing concerns on this filing — trades that line up closely with related legislative or contract activity.
Transactions
1
Companies
1
Largest Trade
$1K-$15K
Timing Flags
4
Companies in this filing
Price Movement Since Trade
How the largest positions have moved from the trade date to the most recent close.
Trade Day
$147.44
Dec 1, 2025
Current
$144.49
Apr 20, 2026
Change
-2.00%
$-2.95
🔒
Sign Up to See More
See the full trade breakdown, suspicious timing flags, and how this filing connects to active legislation.
Get Free Access →Timing Flags
4 flags1.
Rep. Case sold $1,001 - $15,000 in $PG on 2025-12-01 — 16 days before HR6832, which introduces new compliance costs for consumer packaged goods manufacturers, was introduced.
2.
Rep. Case sold $1,001 - $15,000 in $PG on 2025-12-01 — 44 days before HR7050, which introduces stringent FDA oversight for homeopathic products, was introduced.
These flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.
Share This Filing
All Transactions
Connected Legislative Activity
7 signalsThese bills and contracts share tickers or sectors with this filing's trades.
BillHR7050bearish
Homeopathic Drug Product Safety, Quality, and Transparency Act
HR 7050 would end the FDA's long-standing enforcement discretion over homeopathic products and require individual pre-market approval for each product. For CHD, PG, and CLX, the affected product lines represent a small fraction of total revenue. The bill is at the earliest legislative stage and faces a long path to enactment. Market data shows no pricing of this risk: CHD is up 4.02% in 30 days, PG up 1.86%, CLX down 7.02% due to unrelated factors.
Jan 14, 2026
CHDCLXPG
BillHR7502bearish
To prohibit a person from making a misleading recycled content claim in advertising, marketing, selling, or offering for sale a product to a consumer, and for other purposes.
HR7502 proposes a federal standard prohibiting misleading recycled content claims in consumer product marketing. The bill is in early committee stage with 9 cosponsors and limited legislative momentum. For $PG, $KO, $PEP, $KMB, and $CL, the bill imposes added compliance costs with no revenue offset — structurally bearish but low probability of passage in current form.
Feb 11, 2026
CLKMBKOPEPPG
BillHR6832bearish
To amend the Federal Trade Commission Act to include requirements for recyclable, compostable, and reusable claims for packaging for a consumer product, and for other purposes.
The PACK Act (HR6832) introduces new regulatory burdens for consumer packaged goods manufacturers by establishing strict requirements for recyclable, compostable, and reusable claims on product packaging. This bill, currently in the early stages of the legislative process, creates compliance costs for companies like Procter & Gamble, Coca-Cola, and PepsiCo. Recent market data shows mixed performance for these companies, with some experiencing gains and others declines over the past 7 and 30 days.
Dec 17, 2025
CLXGISKHCKOMDLZPEP
BillS3677bearish
Dietary Supplement Listing Act of 2026
The Dietary Supplement Listing Act of 2026 (S.3677) is an early-stage bill that would require mandatory pre-market listing of dietary supplements with the FDA, increasing compliance costs across the industry. The bill is still in committee and faces a long legislative path. If enacted, pure-play supplement companies like Herbalife face margin pressure, while large diversified CPG companies like Kraft Heinz are relatively protected.
Jan 15, 2026
HLF
BillHR6234neutral
Baby Bonus Act
The Baby Bonus Act (HR6234) has been stuck in the House Ways and Means Committee for over five months with no appropriations and no cosponsors from committee leadership. It has zero current or near-term market impact. No tickers meet confidence thresholds for inclusion.
Nov 20, 2025
BillHR5917neutral
To authorize the extension of nondiscriminatory treatment (normal trade relations treatment) to products of certain countries.
HR5917 is an early-stage procedural bill authorizing the President to extend normal trade relations to most countries by waiving the Jackson-Vanik amendment. It authorizes no funding and changes no current tariff levels. Real market data shows $WMT at $130.81 near its 52-week high, with a 30-day gain of 5.25%, and $AAPL up 8.8% in 30 days—indicating that favorable trade expectations are already priced in. The bill faces a long legislative path with no near-term market impact.
Nov 4, 2025
AAPLAMZNWMT
BillHR6370neutral
Baby Changing in Health Centers Act
HR6370 (Baby Changing in Health Centers Act) is an early-stage, narrow procurement bill requiring baby changing tables in federally funded health centers. It authorizes no direct appropriations, has only one cosponsor, and is stuck at committee referral. Real market data shows $KMB trading at $96.82 within its 52-week range with no abnormal volume; this bill has zero material revenue impact on any publicly traded company.
Dec 3, 2025
KMBPG
Other Filings by Ed Case
Free — no credit card
Get the next Case trade the day it's disclosed
HillSignal tracks every Congressional stock filing and federal contract, scores its market impact with AI, and emails you the ones that matter — before they hit the news.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.